Literature DB >> 20702640

Very few substitutions in a germ line antibody are required to initiate significant domain exchange.

Michael Huber1, Khoa M Le, Katie J Doores, Zara Fulton, Robyn L Stanfield, Ian A Wilson, Dennis R Burton.   

Abstract

2G12 is a broadly neutralizing anti-HIV-1 monoclonal human IgG1 antibody reactive with a high-mannose glycan cluster on the surface of glycoprotein gp120. A key feature of this very highly mutated antibody is domain exchange of the heavy-chain variable region (V(H)) with the V(H) of the adjacent Fab of the same immunoglobulin, which assembles a multivalent binding interface composed of two primary binding sites in close proximity. A non-germ line-encoded proline in the elbow between V(H) and C(H)1 and an extensive network of hydrophobic interactions in the V(H)/V(H)' interface have been proposed to be crucial for domain exchange. To investigate the origins of domain exchange, a germ line version of 2G12 that behaves as a conventional antibody was engineered. Substitution of 5 to 7 residues for those of the wild type produced a significant fraction of domain-exchanged molecules, with no evidence of equilibrium between domain-exchanged and conventional forms. Two substitutions not previously implicated, A(H14) and E(H75), are the most crucial for domain exchange, together with I(H19) at the V(H)/V(H)' interface and P(H113) in the elbow region. Structural modeling gave clues as to why these residues are essential for domain exchange. The demonstration that domain exchange can be initiated by a small number of substitutions in a germ line antibody suggests that the evolution of a domain-exchanged antibody response in vivo may be more readily achieved than considered to date.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702640      PMCID: PMC2950590          DOI: 10.1128/JVI.01111-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Three-dimensional domain swapping in p13suc1 occurs in the unfolded state and is controlled by conserved proline residues.

Authors:  F Rousseau; J W Schymkowitz; H R Wilkinson; L S Itzhaki
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

Review 2.  3D domain swapping: as domains continue to swap.

Authors:  Yanshun Liu; David Eisenberg
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

3.  Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12.

Authors:  K H Roux; Ping Zhu; Margaret Seavy; Hermann Katinger; Renate Kunert; Vanessa Seamon
Journal:  Mol Immunol       Date:  2004-08       Impact factor: 4.407

4.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

5.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.

Authors:  Chih-chin Huang; Miro Venturi; Shahzad Majeed; Michael J Moore; Sanjay Phogat; Mei-Yun Zhang; Dimiter S Dimitrov; Wayne A Hendrickson; James Robinson; Joseph Sodroski; Richard Wyatt; Hyeryun Choe; Michael Farzan; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

6.  Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.

Authors:  Katie J Doores; Zara Fulton; Michael Huber; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 7.  Toward oligosaccharide- and glycopeptide-based HIV vaccines.

Authors:  Lai-Xi Wang
Journal:  Curr Opin Drug Discov Devel       Date:  2006-03

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

View more
  36 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.

Authors:  Katie J Doores; Zara Fulton; Michael Huber; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

3.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

Review 4.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

Review 5.  Antibody recognition of HIV and dengue glycoproteins.

Authors:  Isaac J Krauss
Journal:  Glycobiology       Date:  2016-03-03       Impact factor: 4.313

6.  Interrogation of side chain biases for oligomannose recognition by antibody 2G12 via structure-guided phage display libraries.

Authors:  Tsung-Yi Lin; Jonathan R Lai
Journal:  Bioorg Med Chem       Date:  2017-09-15       Impact factor: 3.641

7.  Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Authors:  Yasunori Watanabe; Snezana Vasiljevic; Joel D Allen; Gemma E Seabright; Helen M E Duyvesteyn; Katie J Doores; Max Crispin; Weston B Struwe
Journal:  Anal Chem       Date:  2018-05-25       Impact factor: 6.986

8.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Anti-HIV B Cell lines as candidate vaccine biosensors.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Michael Huber; Emilia Falkowska; Katherine J Doores; Lars Hangartner; Khoa Le; Devin Sok; Joseph Jardine; Jeffrey Lifson; Xueling Wu; John R Mascola; Pascal Poignard; James M Binley; Bimal K Chakrabarti; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

Review 10.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.